Holding(s) in Company

RTW Biotech Opportunities Ltd
16 February 2024
 

TR-1: Standard form for notification of major holdings

1. Issuer Details

ISIN

GG00BKTRRM22

Issuer Name

RTW BIOTECH OPPORTUNITIES LTD

UK or Non-UK Issuer

Non-UK

2. Reason for Notification

Other

Comments

As a result of the recent issuance of new ordinary shares of RTW Biotech Opportunities Ltd ("RTW"), Bluestem's interest in RTW has been diluted to 8.74% which then triggers the notification threshold.

3. Details of person subject to the notification obligation

Name

Bluestem Asset Management, LLC

City of registered office (if applicable)

Charlottesville

Country of registered office (if applicable)

United States

Name

City of registered office

Country of registered office

Bluestem Partners, LP

Wilmington Delaware

USA

4. Details of the shareholder

Full name of shareholder(s) if different from the person(s) subject to the notification obligation, above

 

City of registered office (if applicable)

 

Country of registered office (if applicable)

 

5. Date on which the threshold was crossed or reached

13-Feb-2024

6. Date on which Issuer notified

16-Feb-2024

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8.A)

% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights held in issuer

Resulting situation on the date on which threshold was crossed or reached

8.740000

0.000000

8.740000

34093156

Position of previous notification (if applicable)





8. Notified details of the resulting situation on the date on which the threshold was crossed or reached

8A. Voting rights attached to shares

Class/Type of shares ISIN code(if possible)

Number of direct voting rights (DTR5.1)

Number of indirect voting rights (DTR5.2.1)

% of direct voting rights (DTR5.1)

% of indirect voting rights (DTR5.2.1)

GG00BKTRRM22

34093156

0

8.740000

0.000000

Sub Total 8.A

34093156

8.740000%

8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))

Type of financial instrument

Expiration date

Exercise/conversion period

Number of voting rights that may be acquired if the instrument is exercised/converted

% of voting rights

 





Sub Total 8.B1




8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))

Type of financial instrument

Expiration date

Exercise/conversion period

Physical or cash settlement

Number of voting rights

% of voting rights

 






Sub Total 8.B2




9. Information in relation to the person subject to the notification obligation

2. Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entities (please add additional rows as necessary)

Ultimate controlling person

Name of controlled undertaking

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

Michael D. Bills

Bluestem Asset Management LLC

8.740000

0.000000

8.740000%

10. In case of proxy voting

Name of the proxy holder

 

The number and % of voting rights held

 

The date until which the voting rights will be held

 

11. Additional Information

Michael D. Bills has sole authority for Bluestem Asset Management, LLC, as its Managing Member. Bluestem Asset Management, LLC is the General Partner of the Shareholder, Bluestem Partners, LP, and is authorized to act for Bluestem Partners, LP on all matters.

The last notification was submitted to the FCA and the issuer on 9/28/2020 via email. Bluestem's interest in RTW Venture Fund Limited (as RTW Biotech Opportunities Ltd was formerly known) held thru Vidacos Nominees Limited was 34,093,156 shares or around 18.96%.

12. Date of Completion

16/02/2024

13. Place Of Completion

Charlottesville, VA USA

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UK 100

Latest directors dealings